APR 2 6 2007 BY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Esther H. CHANG et al.)
) Office of Initial Patent Examination
Serial No. 09/716,320) Customer Service Center
)
Filed: 21 November 2000) Group Art Unit: 1645
)
For: COMPOSITIONS AND)
METHODS FOR REDUCING)
RADIATION AND DRUG)
RESISTANCE IN CELLS)

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Dear Sir:

Please issue a corrected Filing Receipt for the above-identified patent application to reflect the following corrections.

Applicant(s) information should be added as follows:

Esther H. Chang, -- Chevy Chase, MD; Kathleen F. Pirollo, Rockville, MD.--

The following continuing data should be added:

--AND IS A CIP OF 09/601,444, 01/04/01, WHICH IS A 371 OF PCT/US98/24657, 11/19/98, WHICH IS RELATED TO 60/066,188, 11/19/97, AND WHICH IS ALSO RELATED TO 60/083,175, 04/27/98.--.

fil

In the Title, please change "METHOD" to --METHODS--.

A copy of the Filing Receipt with the corrections marked in red is attached for your reference.

Respectfully submitted,

Stephen A. Saxe, Ph.D. Registration No. 38,609 Attorney for Applicants

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 701 East, 555 13th Street, N.W.

Washington, D.C. 20004 Telephone: (202) 783-6040



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 2023! www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
	THE THE	0111 71111 01111	THETELETICOD	MITTEDOORETINO		7010241110	III OD (IIVIO
09/716,320	11/21/2000	1645	0	2444-109	12	20	5

Stephen A Saxe Rothwell Figg Ernst & Manbeck 555 13th Street NW Suite 701 East Washington, DC 20004



ot is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be fied as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

CHEVY CHOSE, MD; KATHLEEN F. PIRALO, ROCKVILLE, MD Esther H. Chang, Residence, NOT PROVIDED:

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/480,143 01/10/2000 ABN WHICH IS A CON OF 08/991,830 12/16/1997 PAT 6,027,892

WHICH CLAIMS BENEFIT OF 60/034,160 12/30/1996; and in a CIPO, 09/601 is a 371 of PCT/US98/24657, 11/19/98, which is related

Foreign Applications offen 69066, 188, 11/19/97, and which a also 60/083,175,04/27/98.

If Required, Foreign Filing License Granted 02/24/2001

Title METHODS

Compositions and method for reducing radiation and drug resistance in cells

Preliminary Class

435

Data entry by : HOPKINS, AUDREY

Team: OIPE

Date: 02/26/2001



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls. Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231